ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-Wynne

ASCO 2023 Expert Report on novelties in oncogene driven NSCLC by A. Curioni-FontecedroПодробнее

Conceptualizing Guidelines to Manage Patients with HR–Positive, HER2-Negative Early Breast CancerПодробнее

What to look forward to in breast cancer at ASCO 2023Подробнее

Expert Report on advances in the management of HER2-negative and HER2-low advanced breast cancerПодробнее

HER2-low breast cancer: the ESMO Expert Consensus StatementsПодробнее

Key challenge associated with the management of HR+/HER2- breast cancerПодробнее

HER2/neu Positive or HER2/neu enriched Cancer | A Type of breast cancer | Dr Jay R. AnamПодробнее

ASCO 2023 Expert Report on novelties in the treatment of colorectal cancer by S. StintzingПодробнее

Breast Cancer Breakthroughs Episode 3: Highlights from ASCO 2023Подробнее

Expert Report on novel data in (neo)adjuvant treatment of melanoma from ASCO 2022Подробнее

Top breast cancer abstracts at ASCO 2023: NATALEE and PHERGainПодробнее

Standard of care practice in Adjuvant HR+ Breast Cancer before ASCO 2023 #oncology #ASCO2023 #cancerПодробнее

Historical Perspective on HR+/HER2- Breast Cancer: 2023 KU Breast Cancer Year in ReviewПодробнее

Triple negative or Her2+? Check this out!Подробнее

New and emerging agents in HER2-negative metastatic breast cancer: Implications for practiceПодробнее